Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells

Cancer Gene Therapy

Volumn 14, Issue 5, 2007, Pages 441-450

  Goding, S ^a,b   Yang, Q ^a,b   Mi, Z ^c   Robbins, P D ^b,c   Basse, P H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

A NK cell; Adenovirus; B16 melanoma; T LAK cell; Tumor localization

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; ENHANCED GREEN FLUORESCENT PROTEIN; GENE PRODUCT; INTERLEUKIN 12; INTERLEUKIN 2; LUCIFERASE; PHYTOHEMAGGLUTININ; RED FLUORESCENT PROTEIN;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; LUNG METASTASIS; LYMPHOCYTE HOMING; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TARGET ORGAN; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; GALACTOSIDASES; GENE THERAPY; GREEN FLUORESCENT PROTEINS; INTERLEUKIN-12; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LUCIFERASES; LUNG NEOPLASMS; MICE; MICE, INBRED STRAINS; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 34247158603     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701019     Document Type: Article

References (41)

1. Tasaki K, Yoshida Y, Miyauchi M, Maeda T, Takenaga K, Kouzu T et al. Transduction of murine colon carcinoma cells with interleukin-15 gene induces antitumor effects in immunocompetent and immunocompromised hosts. Cancer Gene Ther 2000; 7: 255-261.
2. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J Invest Dermatol 2002; 119: 541-548.
3. Lasek W, Basak G, Switaj T, Jakubowska AB, Wysocki PJ, Mackiewicz A et al. Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother 2004; 53: 363-372.
4. Tasaki K, Tagawa M, Gunji Y, Matsubara H, Takenaga K, Muramatsu M et al. Inhibition of experimental lung metastasis of murine colon carcinoma cells depends on the amount of interleukin-2 secreted from the transduced cells. Anticancer Res 1998; 18: 813-817.
5. Slos P, De Meyer M, Leroy P, Rousseau C, Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther 2001; 8: 321-332.
6. Hwang KS, Cho WK, Yoo J, Seong YR, Kim BK, Kim S et al. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity. Cancer Gene Ther 2004; 11: 397-407.
7. Kanno H, Hattori S, Sato H, Murata H, Huang FH, Hayashi A et al. Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-gamma. Cancer Gene Ther 1999; 6: 147-154.
8. Bubenik J, Voitenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubenikova D et al. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett 1988; 19: 279-282.
9. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000; 60: 1111-1116.
10. Ryuke Y, Mizuno M, Natsume A, Suzuki O, Nobayashi M, Kageshita T et al. Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy. Melanoma Res 2003; 13: 349-356.
11. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59: 4035-4041.
12. Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2: 337-349.
13. Halin C, Gafner V, VillaniME, Borsi L , BerndtA,Kosmehl H et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003; 63: 3202-3210.
14. Bauerschmitz GJ, Kanerva A, Wang M, Hermann I, Shaw DR, Strong TV et al. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int J Cancer 2004; 111: 303-309.
15. Sakurai F, Terada T, Maruyama M, Watanabe Y, Yamashita F, Takakura Y et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther 2003; 10: 661-668.
16. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K et al. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 1991; 174: 479-488.
17. Kjaergaard J, Hokland M, Nannmark U, Hokland P, Basse P. Infiltration patterns of short- and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy. Scand J Immunol 1998; 47: 532-540.
18. Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 1997; 11: 615-623.
19. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
20. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
21. Wickham TJ, Tzeng E, Shears II LL, Roelvink PW, Li Y, Lee GM et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
22. Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC et al. Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer 2003; 105: 512-519.
23. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 1989; 142: 1748-1754.
24. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874-882.
25. Perussia B, Chan SH, D'Andrea A, Tsuji K, Santoli D, Pospisil M et al. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol 1992; 149: 3495-3502.
26. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 1199-1204.
27. Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179: 1273-1283.
28. Basse PH, Goldfarb RH, Herberman RB, Hokland ME. Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. In vivo 1994; 8: 17-24.
29. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999; 29: 1390-1396.
30. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999; 163: 583-589.
31. Arai N, Akamatsu S, Arai S, Toshimori Y, Hanaya T, Tanimoto T et al. Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-gamma in vivo. J Interferon Cytokine Res 2000; 20: 217-224.
32. Carson WE, Yu H, Dierksheide J, Pfeffer K, Bouchard P, Clark R et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999; 162: 4943-4951.
33. Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood 2000; 96: 1465-1473.
34. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M et al. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol 1998; 160: 1742-1749.
35. Harrington KJ, Bateman AR, Melcher AA, Ahmed A, Vile RG. Cancer gene therapy: Part 1. Vector development and regulation of gene expression. Clin Oncol (R Coll Radiol) 2002; 14: 3-16.
36. Kovesdi I, Brough DE, Bruder JT, Wickham TJ. Adenoviral vectors for gene transfer. Curr Opin Biotechnol 1997; 8: 583-589.
37. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Therapy 1996; 3: 802-810.
38. Smith JS, Keller JR, Lohrey NC, McCauslin CS, Ortiz M, Cowan K et al. Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens. Proc Natl Acad Sci USA 1999; 96: 8855-8860.
39. Schleef RR, Olman MA, Miles LA, Chuang JL. Modulating the fibrinolytic system of peripheral blood mononuclear cells with adenovirus. Hum Gene Ther 2001; 12: 439-445.
40. Chen Z, Ahonen M, Hamalainen H, Bergelson JM, Kahari VM, Lahesmaa R. High-efficiency gene transfer to primary T lymphocytes by recombinant adenovirus vectors. J Immunol Methods 2002; 260: 79-89.
41. Kjaergaard J, Hokland ME, Agger R, Skovbo A, Nannmark U, Basse PH. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals. Cancer Immunol Immunother 2000; 48: 550-560.